Cisplatin plus standard-of-care gemcitabine/nab-paclitaxel improved tumor shrinkage in patients with metastatic pancreatic cancer, according to a study by the HonorHealth Research Institute and the Translational Genomics Research Institute.
Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.
An investigation into whether onset or worsening of diabetes causes pancreatic cancer or vice versa was presented at the 2017 European Cancer Congress.
Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.
PDX1 appears to have distinct roles at different stages of pancreatic cancer development.
Seluminitinib in combination with an AKT inhibitor did not improve survival compared with modified FOLFOX in previously treated metastatic pancreatic cancer.
Favorable Perioperative Outcomes After Resection of Borderline Resectable Pancreatic Cancer Treated With Neoadjuvant Stereotactic Radiation and Chemotherapy Compared with Upfront Pancreatectomy for Resectable Cancer
[Journal of Gastrointestinal Oncology] This research examines outcomes related to the use of neoadjuvant multi-agent chemotherapy and stereotactic body radiation therapy (SBRT) in borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) patients.
Research findings reveal the mechanism by which obesity increases inflammation and desmoplasia in the most frequent type of pancreatic cancer, using mouse models and human tissue samples.
Systematic Palliative Care Provides Greater Improvement in Quality of Life for Patients with Pancreatic Cancer
Quality of life is significantly improved for patients with pancreatic cancer when systematic palliative care is administered vs on-demand palliative care.
Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.
Combining a laboratory ultrasound technique called sonoporation with the commercially available chemotherapy compound gemcitabine increases the porosity of pancreatic cells with microbubbles and helps get the drug into cancer cells.
Despite the increased risk, patients whose pancreatic cancer tumor has grown to encompass critical blood vessels can be candidates for surgery. Data on efforts to fine-tune a protocol for these patients were presented at the SSAT 57th Annual Meeting.
Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.
Chemoradiotherapy Showed No Survival Benefit Over Chemotherapy in Locally Advanced Pancreatic Cancer
Researchers discovered no survival benefit of chemoradiotherapy over chemotherapy in treating locally advanced pancreatic cancer in the LAP01 Randomized Clinical Trial.
Barriers to Understanding Pancreatic Cancer Can Be Overcome With Improvements to Online Health Information
Available information on pancreatic cancer was written at too high a level and contained inaccuracies regarding alternative therapies, a recent study has shown.
Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy
[Journal of Gastrointestinal Oncology] This research reviews the case history of a patient with stage IVB pancreatic adenocarcinoma initially treated with gemcitabine and erlotinib who stopped therapy after 3 months without achieving a response and was switched to a different and effective combination strategy.
A small molecule that inhibits RAS protein interactions offers hope for targeting this elusive protein. It is one of the most sought-after cancer targets for drug developers, but the mutant RAS protein lacks drug-binding pockets.
Lowest accuracy scores for alternative tx websites; websites with higher accuracy more difficult to read
New research indicates a far greater efficacy in pancreatic cancer drug therapy delivered via implantable device than via IV.
An experimental therapy looks to hold promise for tumor control treatment in pancreatic adenocarcinoma.
Two strains of oral bacteria -- P. gingivalis and A. actinomycetemcomitans -- have been linked to higher risk of pancreatic cancer.
An experimental immune therapy can re-educate macrophages to tear down the scaffolding that surrounds and protects pancreatic cancer from chemotherapy.
Adding radiotherapy to chemotherapy and surgery reduced the number of local disease recurrences but did not affect distant recurrences or survival.
Researchers identified four classes of genetic error that triggered pancreatic tumors and classified pancreatic cancer as four separate diseases.
A natural extract from the neem tree of India is found to have potential as a treatment for pancreatic cancer.
An implantable device allows large doses of highly toxic drugs to be delivered directly to pancreatic tumors while reducing exposure to the toxic side effects in the rest of the body.
Use of a nanoparticle to deliver drugs may reduce tumors and suppress metastatic escape. These efforts offer a way to control drug release over space and time while reducing systemic drug exposure and the associated side effects.
The metabolism of pancreatic cancer cells is altered by the anticancer activity of CDK4/6 inhibitors. Researchers hope this biologic vulnerability could be exploited to treat pancreatic cancer.
The addition of leucovorin to S-1 significantly improved progression-free survival compared with S-1 alone in patients with advanced pancreatic cancer who were refractory to gemcitabine.
Family members of patients with cancers of unknown primary (CUP) are at higher risk of developing CUP themselves, as well as cancers of the lung, pancreas, and colon and some cancers of the blood.
Blood samples collected from the portal vein can tell physicians far more about a patient's pancreatic cancer than peripheral blood collected from a more easily accessed vein in the arm.
Investigational Drug Is Effective Against Debilitating Adverse Effect of Cancer in Preclinical Trials
New data describes how an experimental drug can stop the debilitating and life-threatening adverse effect cachexia commonly associated with advanced cancers and restore muscle health.
RNA test of blood platelets can detect, classify, and pinpoint the location of cancer by analyzing a sample equivalent to 1 drop of blood. Using this new method, researchers were able to identify cancer with 96% accuracy.
Nanoliposomal irinotecan in combination with fluorouracil and folinic acid improves survival in patients with pancreatic ductal adenocarcinoma.
Study findings may explain why chemotherapy drugs such as gemcitabine are not effective for many patients with pancreatic cancer, and perhaps point to new approaches to treatment including enhancing gemcitabine's ability to stop tumor growth.
A widely available, inexpensive blood test can predict outcomes and guide treatment in pancreatic cancer; however, only 1 in 5 US patients with the disease have the blood test.
Concurrent Radiotherapy With Oral Fluoropyrimidine Versus Gemcitabine in Locally Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
[OncoTargets and Therapy] This research evaluates the efficacy and toxicities of oral FU-based CRT compared with GEM-based CRT for the treatment of locally advanced pancreatic cancer (LAPC).
The search for evidence to support the growing use of proton therapy for more cancers continues to uncover valuable findings. New data from clinical trials demonstrate the potential advantages of proton therapy over conventional radiation for pancreatic cancer, late-stage non-small cell lung cancer, chordoma, and chondrosarcoma.
A new drug for the treatment of advanced (metastatic) pancreatic cancer received FDA approval.
Researchers have shown that a certain protein becomes overabundant in pancreatic neuroendocrine tumors, allowing them to thrive. They also found that pairing a synthetic compound with an existing drug provides a more effective anticancer punch than a single drug.
Use of irreversible electroporation (IRE) doubles survival time for patients with locally advanced pancreatic cancer.
Study found IRE procedure improved survival for people with stage III disease.
A new set of genes has been identified that can indicate improved survival after surgery for patients with pancreatic cancer. The study also showed that detection of circulating tumor DNA in the blood could provide an early indication of tumor recurrence.
Scientists have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease metastasizes.
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy compared with younger patients with metastatic disease.
Chemoradiotherapy was independently associated with improved overall survival after the resection of pancreatic adenocarcinoma.
Pain management of pancreatic head adenocarcinomas that are unresectable: Celiac plexus neurolysis and splanchnicectomy
[Journal of Gastrointestinal Oncology] This articles outlines pertinent anatomy, techniques, side effects, complications, and efficacy of interventions for palliation of pain from pancreatic cancer.
Elevated levels of three proteins were detected in the urine of patients with early-stage pancreatic cancer.
Results of blood tests to detect DNA shed from tumors were found to predict cancer recurrence far earlier than standard imaging methods.
A three-protein signature can identify the most common form of pancreatic cancer at an early stage.
A particular microRNA could prove to be a potent therapeutic agent against pancreatic cancer, according to new research.
A protein encoded by the gene glypican-1 present on cancer exosomes may be used as part of a potential non-invasive screening tool to detect early pancreatic cancer.
People with pancreatic cancer or ampullary cancer reported very high levels of needs.
A protein encoded in the glypican-1 (GPC1) gene may allow for a non-invasive screening tool to detect early pancreatic cancer.
A common antibiotic, when combined with an experimental drug, may have a role in pancreatic cancer treatment.
Stereotactic body radiotherapy appears to be both effective and safe for treatment of advanced pancreatic cancer tumors.
Individuals who live in regions with low sunlight may have a higher risk of pancreatic cancer, and shortage of vitamin D may be to blame.
An early stage trial for mesothelioma and pancreatic and ovarian cancers has explored utilizing a patient's own immune cells, genetically modified to target tumors.
A magnetic resonance imaging (MRI)-based screening program for persons at high risk of pancreatic cancer identified pancreatic lesions in 40% of patients, according to an online report.
A new study finds the medication doesn't increase survival rates for patients with pancreatic ductal adenocarcinoma.
Therapy with metformin use did not improve survival of patients with pancreatic ductal adenocarcinoma (PDAC), according to recent study data.
Risk reduction appears sex specific, with significant reduction seen for men, but not women.
New research indicates that magnetic resonance imaging (MRI) might have a role in early detection for those at high genetic risk of pancreatic cancer.
Researchers developed a profile of the patient who would be at highest risk for developing pancreatic lesions.
Present barriers for the usual dosimetry accompanying photodynamic therapy (PDT) for late-stage pancreatic cancer can be overcome via clinical technologies.
MRI-based screening may be effective in identifying high-risk pancreatic cancer.
New guidelines for pancreatic cyst management recommend surveillance for low-risk cysts, discontinuation after no change for five years.
Researchers have developed a device that uses electric fields to drive chemotherapy drugs through the protective barrier of tissue and directly into pancreatic tumors, preventing their growth.
New study helps explain why pancreatic cancer is so lethal, with less than one-third of patients surviving even early stage disease.
Patients with pancreatic cancer face a poor prognosis, as only approximately 6% of patients survive.
How much more toxicity and myelosuppression has been associated with gemcitabine (Gemzar) when it is infused over periods longer than 30 minutes?
A recent study may dispel the myth that cancer biopsies have a role in the spreading of cancer in the body.
A new technique allows discovery of unknown pancreatic cancer genes previously invisible to standard genetic sequencing.
Is there an effective way to manage the oral side effects of irinotecan therapy?
Pancreatic cancer may potentially be safely and effectively treated with immunochemotherapy, according to recent research from a preclinical study.
Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.
Increased expression of a microRNA (miRNA) panel seems highly accurate for diagnosis of pancreatic ductal adenocarcinoma (PDAC), according to a study published online.
New research that provides a better understanding of pancreatic cancer may help identify those people at increased risk.
Patients with a family history of pancreatic cancer may be at an increased risk for developing the disease.
An analysis of circulating tumor cells (CTCs) in a pancreatic cancer model identified several different classes of CTCs and found unexpected factors that may prove to be future targets for improved treatment.
After surviving pancreatic cancer, a patient learns the disease metastasized to his liver. But this patient was not ready to give up. With the support of a liver surgeon, he underwent surgery and beat his disease.
Is there a good reason to mix nab-paclitaxel (Abraxane) with warm (not cool) normal saline when reconstituting?
Findings based on comparison to sulfonylureas and thiazolidinediones
Gemcitabine in combination with simtuzumab 200 mg or 700 mg did not significantly increase progression-free survival.
Chokeberry, a wild berry, may improve the effectiveness of gemcitabine for the treatment of pancreatic cancer.
A new use for an old drug shrinks a particular type of pancreatic cancer and stops it from spreading, according to new research.
A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, reported scientists.
Adequate hydration via a saline drip is essential during surgery, but recent reports suggest that getting the balance of salt and water just right could have an important impact on patient recovery.
Investigators are developing a novel, multistep investigational treatment for locally advanced pancreatic cancer, which is complex and difficult to treat.
The protein galectin-1 has been identified as a possible therapeutic target for pancreatic cancer; new research has demonstrated that inhibiting this protein in mice with pancreatic cancer increased survival by 20%.
Pancreatic cancers dependent on signaling from a mutant Kras gene for their growth and progression in the laboratory are able to switch to Yap1, another oncogene, if Kras is blocked.
The addition of MM-398, a novel nanoliposome formulation of irinotecan, to standard treatment improves survival for metastatic pancreatic cancer patients who have already received gemcitabine.
A new vaccine triggered the growth of immune cell nodules within pancreatic tumors, reprogramming these intractable cancers and making them vulnerable to immune-based therapies.
Results of a phase I clinical trial of a vaccine therapy for pancreatic cancer indicate the treatment is well tolerated; in addition, it suggests that the vaccine stabilizes the disease for a period of time.
Guidelines from the Fred Hutchinson Cancer Research Center advise that low-dose daily aspirin for prevention of pancreatic cancer may not be for everyone.
People who take low-dose aspirin for more than 10 years might be reducing their risk for pancreatic cancer, a new study suggests.
A clinical trial showed that the new drug MM-398, given in combination with 5-flourouracil (5-FU) and leucovorin, produced a significant overall survival rate in patients with advanced pancreatic cancer.
An optical blood oxygen sensor attached to an endoscope is able to identify pancreatic cancer in patients via a simple endoscopic procedure, according to researchers.
Fibrous tissue long suspected of making pancreatic cancer worse actually supports an immune attack that slows tumor progression but cannot overcome it, scientists have reported.
A mutated gene common to adenosquamous carcinoma tumors has been identified. It is the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Comparison of Survival Outcomes Between Radical Hysterectomy and Definitive Radiochemotherapy in Stage IB1 and IIA1 Cervical Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|